- Home
- Publications
- Publication Search
- Publication Details
Title
Brivanib alaninate for cancer
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 20, Issue 4, Pages 577-586
Publisher
Informa Healthcare
Online
2011-03-11
DOI
10.1517/13543784.2011.565329
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Correlation of FGF2 tumor expression with tumor response, PFS, and changes in plasma pharmacodynamic (PD) markers following treatment with brivanib alaninate, an oral dual inhibitor of VEGFR and FGFR tyrosine kinases
- (2017) S. Platero et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I study of brivanib alaninate (BMS-582664), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full dose cetuximab (BC) in patients (pts) with advanced gastrointestinal malignancies (AGM) who failed prior therapy
- (2017) C. R. Garrett et al. JOURNAL OF CLINICAL ONCOLOGY
- Angiogenesis Inhibitors: Current Strategies and Future Prospects
- (2010) K. M. Cook et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Targeted therapies of cancer: Angiogenesis inhibition seems not enough
- (2010) Ilse Roodink et al. CANCER LETTERS
- FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
- (2010) N. Turner et al. CANCER RESEARCH
- The Antiangiogenic Activity in Xenograft Models of Brivanib, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinases
- (2010) R. S. Bhide et al. MOLECULAR CANCER THERAPEUTICS
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
- Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate
- (2009) Christine Y. Shiang et al. BREAST CANCER RESEARCH AND TREATMENT
- Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate
- (2009) Punit H. Marathe et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors
- (2009) A. Craig Lockhart et al. JOURNAL OF CLINICAL ONCOLOGY
- Validation of 70-gene prognosis signature in node-negative breast cancer
- (2008) J. M. Bueno-de-Mesquita et al. BREAST CANCER RESEARCH AND TREATMENT
- Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma
- (2008) H. Huynh et al. CLINICAL CANCER RESEARCH
- 429 POSTER Phase 1 study of food effects on pharmacokinetics of brivanib alaninate in patients with advanced or metastatic solid tumors
- (2008) H. Hurwitz et al. EJC SUPPLEMENTS
- Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors
- (2008) Margaret A Knowles Future Oncology
- “Stemness” Genomics Law Governs Clinical Behavior of Human Cancer: Implications for Decision Making in Disease Management
- (2008) Gennadi V. Glinsky JOURNAL OF CLINICAL ONCOLOGY
- Discovery of Brivanib Alaninate ((S)-((R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), A Novel Prodrug of Dual Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinase Inhibitor (BMS-540215)
- (2008) Zhen-wei Cai et al. JOURNAL OF MEDICINAL CHEMISTRY
- Drug-sensitive FGFR2 mutations in endometrial carcinoma
- (2008) A. Dutt et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started